-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Buy on Biomarin Pharmaceutical, Lowers Price Target to $104

Benzinga·05/05/2025 14:54:05
Listen to the news
Goldman Sachs analyst Salveen Richter maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Buy and lowers the price target from $124 to $104.